Scholar Rock (SRRK)
(Delayed Data from NSDQ)
$7.42 USD
+0.35 (4.95%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $7.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SRRK 7.42 +0.35(4.95%)
Will SRRK be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for SRRK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRRK
Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High?
Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK)
SRRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy
Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 203.99%: Read This Before Placing a Bet
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
Other News for SRRK
Scholar Rock price target raised by $2 at Wedbush, here's why
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock: Enrollment complete in Phase 2 trial of apitegromab for obesity
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer